Leucémie myéloïde aiguë (LMA)

  • Accueil
  • Leucémie myéloïde aiguë (LMA)
  • M19-708 (VIALE-M)

TITRE (EN) Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
PROTOCOLE ID M19-708 (VIALE-M)
CLINICAL TRIAL.gov ID NCT04102020
TYPE(S) DE CANCER Leucémie myéloïde aiguë (LMA)
PHASE Phase III
TYPE D'ÉTUDE Clinique
INSTITUTION CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) John Storring
COORDONATEUR(RICE)
STATUT  Fermé
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Diagnosis of newly diagnosed acute myeloid leukemia (AML).

  • Participant meets the following disease activity criteria:

    • Confirmation of AML by World Health Organization (WHO) criteria (2016) and have confirmed complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following completion of planned induction and consolidation chemotherapy.
    • Achieved first CR + CRi within 4 months of enrollment or be no more than 75 days since last dose of conventional therapy.
    • AML has intermediate or poor risk cytogenetics per National Comprehensive Cancer Network (NCCN) 2016 criteria.
  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
  • Participant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.
CRITÈRES D'EXCLUSION (EN)
  • History of acute promyelocytic leukemia (APL).
  • History of active central nervous system involvement with acute myeloid leukemia (AML).